Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 724
- Registration Number
- NCT00708162
- Locations
- 🇺🇸
Whitman-Walker Clinic, Washington, District of Columbia, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Dallas VA Medical Center
- Target Recruit Count
- 85
- Registration Number
- NCT00677300
- Locations
- 🇺🇸
Dallas VA Medical Center, Dallas, Texas, United States
🇺🇸Parkland Health & Hospital System, Dallas, Texas, United States
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2013-07-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 18
- Registration Number
- NCT00672932
- Locations
- 🇺🇸
Ucsf Ccrc, Sfgh, San Francisco, California, United States
A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT00666705
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00665717
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 25
- Registration Number
- NCT00661960
- Locations
- 🇺🇸
CARES Clinic, Sacramento, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 40
- Registration Number
- NCT00660972
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸Ohio State University CRS, Columbus, Ohio, United States
Raltegravir Therapy for Women With HIV and Fat Accumulation
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 39
- Registration Number
- NCT00656175
- Locations
- 🇨🇦
University Health Network, Toronto, Toronto, Ontario, Canada
🇺🇸Case School of Medicine, Cleveland, Ohio, United States
🇺🇸UCLA CARE Center, Los Angeles, California, United States
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
- Conditions
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 6
- Registration Number
- NCT00632970
- Locations
- 🇺🇸
George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Raltegravir Intensification in HIV-infected Patients
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT00631449
- Locations
- 🇺🇸
San Francisco General Hospital, Clinical Research Center, San Francisco, California, United States
🇺🇸San Francisco Veterans Affairs Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.